💸 The Tape

There's a particular kind of cruelty in telling someone their condition is terminal — and then telling them the one thing that eases their pain isn't welcome within the walls of the facility treating them.

The Louisiana Senate is trying to fix that. On Wednesday, the body passed SB 270 in a lopsided 33-2 vote, advancing legislation that would allow patients with terminal and irreversible conditions to use medical marijuana inside hospitals. The bill, sponsored by Sen. Katrina Jackson-Andrews (D), now heads to the House of Representatives.

The mechanics are straightforward. Under the proposal, hospitals would be required to create written guidelines permitting covered patients to consume medical cannabis on-site in forms other than smoking or vaping. Patients or their primary caregivers would be responsible for acquiring, administering, and securely storing the product in a locked container. Hospital staff would be explicitly prohibited from handling, storing, or assisting with the marijuana — a boundary designed to shield healthcare workers and institutions from federal exposure.

An amendment crafted with input from the Louisiana Hospital Association added further guardrails: emergency and outpatient departments are exempted, and hospitals retain the ability to opt out entirely if federal authorities take enforcement action against any healthcare facility in the state over medical cannabis use.

Jackson-Andrews framed the bill in the most human terms possible: "When a patient is in pain and they believe that therapeutic marijuana will work and have a prescription for it, it allows them to have that prescription delivered to the hospital."

Simple enough. But the implications are anything but.

The Hospital Door Problem

Medical marijuana is now legal in 38 U.S. states, and the list of qualifying conditions has expanded steadily over the past decade. Yet for all that legislative progress, one glaring contradiction has persisted: the moment a patient walks through a hospital entrance, their legal medicine effectively becomes contraband.

Hospitals operate under federal funding structures — most critically, Medicare and Medicaid reimbursements — that are governed by federal law. And under federal law, cannabis remains a Schedule I controlled substance. That classification creates an institutional risk calculus where even the most compassionate hospital administrator hesitates to allow a substance on-site that could theoretically jeopardize their facility's funding.

The result is a system where a terminally ill patient can legally purchase medical cannabis, legally use it at home, and then be told they cannot access it during the very period when they arguably need it most — while receiving end-of-life care in a hospital bed.

Louisiana's bill doesn't eliminate the federal tension. But it does something arguably more important: it forces the healthcare system to acknowledge the disconnect and build a framework for navigating it rather than simply defaulting to prohibition.

A Shift in Institutional Legitimacy

What makes SB 270 significant isn't just the policy mechanics — it's the signal it sends about how medical institutions relate to cannabis as a therapeutic tool.

For years, the medical establishment has existed in an awkward liminal space regarding marijuana. Physicians in legal states can recommend it. Pharmacies affiliated with state programs can dispense it. Research increasingly supports its efficacy for chronic pain, nausea, appetite stimulation, and various other conditions common in terminal illness. Yet hospitals — the very epicenter of medical care — have largely kept cannabis at arm's length, treating it as something that happens outside their jurisdiction.

Allowing medical marijuana inside hospitals, even with the significant restrictions Louisiana's bill imposes, represents a philosophical shift. It moves cannabis from the periphery of the healthcare conversation toward something closer to institutional acceptance. When a hospital creates formal written guidelines for cannabis use, it is, in effect, integrating marijuana into the continuum of patient care — not as a rogue alternative, but as a recognized component of comfort and treatment.

That matters enormously for patient dignity. Terminal illness already strips people of control over their bodies, their routines, their futures. Being denied access to a legally prescribed treatment while confined to a hospital bed adds an unnecessary layer of indignity to an already devastating experience. Legislation like SB 270 restores a small but meaningful measure of patient autonomy at a time when autonomy is in desperately short supply.

The Opioid Shadow

There's another dimension to this conversation that Louisiana's bill doesn't explicitly address but that looms large in the background: opioids.

Hospitals routinely administer powerful opioid painkillers to terminal patients — medications with well-documented risks of dependency, respiratory depression, and a host of debilitating side effects. The irony that a patient can receive morphine through an IV drip but cannot consume a cannabis-infused lozenge brought from home is not lost on advocates.

A growing body of research suggests that marijuana can help patients reduce opioid use, potentially offering pain management with a more tolerable side-effect profile. For terminal patients in particular — individuals for whom addiction risk is largely irrelevant — the case for allowing cannabis access alongside or in place of opioids is difficult to argue against on medical grounds. The objections that remain are almost entirely legal and bureaucratic.

What Comes Next

Louisiana's bill still needs to clear the House, and the opt-out provision means hospitals retain significant discretion. Federal enforcement risk, while currently low under most administrations, remains the elephant in every room where this conversation takes place.

But the 33-2 Senate vote suggests the political appetite for this kind of reform is substantial. And Louisiana is unlikely to be the last state to confront the hospital access question. As more states legalize medical cannabis and patient populations grow, the pressure on healthcare institutions to accommodate rather than exclude will only intensify.

The broader takeaway is this: medical marijuana's journey toward full legitimacy doesn't end at the dispensary counter. It ends when the institutions we trust most with our health — hospitals, clinics, care facilities — treat it not as a regulatory liability, but as what it increasingly appears to be: medicine.

For terminally ill patients in Louisiana, that door may finally be opening.

Source: Marijuana Moment

📈 Dog Walkers

$VFF ( ▲ 1.88% ) Rolls Out Potency Program

For years, cannabis packaging has told consumers a comforting little fiction: one tidy THC percentage, printed with the confidence of a lab result that suggests every bud in the bag is identical. Pure Sunfarms is calling time on that convention.

Village Farms International announced that its Canadian cannabis brand has become the first to introduce THC potency ranges on dried flower packaging in the Canadian recreational market. The pilot program launches with Pink Kush in British Columbia and builds on the company's recently published research into THC variability across cannabis flower.

The concept is refreshingly straightforward. Instead of stamping a single number on the package, Pure Sunfarms now displays a potency range reflecting how the cultivar consistently performs over time. It's a subtle but meaningful shift — one that acknowledges what anyone in agriculture already knows: cannabis is a plant, and plants vary.

Orville Bovenschen, Global President of Operations for Village Farms, put it plainly: the industry has been anchored to a fixed potency number for too long. A range gives consumers a more honest expectation of what's actually inside the bag. He also emphasized that THC is only one piece of the puzzle — aroma, terpene profile, bud structure, density, and trim quality all shape how flower performs for the end user.

The choice to start with Pink Kush is deliberate. As one of Pure Sunfarms' flagship cultivars and a consistently top-selling SKU nationally, it offers high visibility and consumer familiarity. Early consumer research reportedly shows strong interest in and understanding of the range-based approach.

It's a small change on a label, but it signals something larger: a maturing industry starting to communicate quality with the kind of transparency consumers actually deserve.

$RYM ( ▲ 1.71% ) Gets Nutty

Two great tastes that taste great together just got a THC upgrade.

incredibles, the award-winning edibles brand owned by RYTHM, Inc., is launching Peanut Buddah Cups — and yes, they're exactly what they sound like. Creamy peanut butter meets smooth milk chocolate, each cup infused with 25 mg THC and 25 mg CBG, with six cups per pack. It's the kind of product that feels less like innovation and more like inevitability.

The THC-CBG blend is designed to deliver what the brand calls a "melt-into-the-moment experience" — a balanced, relaxing effect that pairs nicely with the indulgent flavor profile. For a brand that built its reputation on making edibles that actually taste good, the peanut butter cup format feels like a natural home run.

Eli Weiner, Senior Brand Manager at incredibles, said the launch reflects a simple philosophy: give consumers their favorite flavors in familiar formats with doses that perform. "Peanut Buddah Cups check every box," he noted, adding that the brand is focused on building the best-tasting edibles portfolio on the market while pushing the category on potency and consistency.

The new cups join an already stacked lineup that includes the fan-favorite Peanut Budda Buddha Bar and a collaboration series with Magnolia Bakery. That portfolio has been paying off — according to BDSA's U.S. retail sales tracking for 2025, incredibles ranked as the No. 1 chocolate brand in the nation.

Each cup is crafted with 100% hemp-derived THC and CBG using a precision infusion process to ensure accurate dosing across every piece. They're available for delivery directly at iloveincredibles.com.

For the cannabis consumer with a sweet tooth and high standards, the Buddah has arrived.

🗞️ The News

📺 YouTube

Breaking Down The Cannabis Buzz This Week | TTB Presented by Flowhub

What we will cover:

✅ Host Anthony Varrell sits down with Adam Stettner, Founder and CEO of FundCanna, the leading cannabis-focused lender that has approved over $300 million in funding across 40 states for cultivators, manufacturers, distributors, retailers, and ancillary businesses.

In this episode, we break down the biggest cannabis headlines of the week — starting with the social equity story that operators and investors need to watch. Ascend Wellness Holdings just announced a partnership with NuProject to launch ROOTS (Readying Opportunities for Operational & Trade Sustainability), a six-month business readiness program for small cannabis businesses in Massachusetts and New Jersey. The program provides coaching, financial mentorship, and direct access to Ascend's corporate supply chain — a real model for how MSOs can create pathways for equity operators. Meanwhile, Vireo Growth made waves with a strategic partnership transferring 51% ownership of Vireo Health of New York to Ace Ventures, a minority and women-owned enterprise led by Steven Acevedo. This is expected to become New York's first scaled social equity operator built from a vertically integrated medical cannabis license. We discuss what these moves signal for the future of social equity in cannabis.